Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Large meta-analysis sheds new light on how SGLT2 inhibitors affect blood and iron parameters (opens in a new tab)

medicalxpress.com · 2026-10-26

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredPatients receiving SGLT2 inhibitors showed higher erythropoietin concentrations, while transferrin saturation and ferritin decreased and serum iron remained largely unchanged.View evidenceHide evidence

Why this verdict

The abstract-level profile supports higher erythropoietin and lower transferrin saturation. However, it does not provide abstract-level results verifying that ferritin decreased or that serum iron remained largely unchanged; it notes only that 4 of 6 secondary outcomes were significant without enumerating all estimates.

1

Study evidence

SGLT2 inhibitor use was associated with a small increase in erythropoietin (EPO) compared with control in pooled randomized trials.Difference in change: 2.11 mIU/mL (95% CI, 0.50 to 3.71; P = .01).

“Secondary outcomes were changes in red blood cell concentration, erythropoietin (EPO), and iron measures (serum iron, ferritin, transferrin saturation, and hepcidin).”
Claim 2 of 5Not coveredThe article says the clinical significance of these blood and iron changes remains uncertain, and it is not yet clear whether they directly contribute to cardiovascular and kidney benefits.View evidenceHide evidence

Why this verdict

The profile supports the statement that the clinical significance of the hematologic and biomarker changes is unclear. At abstract depth, however, it does not specifically verify the claim about whether these changes directly contribute to cardiovascular and kidney benefits.

1

Study evidence

SGLT2 inhibitor use was associated with a greater increase in hemoglobin from baseline to follow-up compared with control.Difference in change: +0.60 g/dL (95% CI, 0.55 to 0.66 g/dL); P < .001

“A Systematic Review and Meta-Analysis of Randomized Clinical Trials.”
2

Study evidence

SGLT2 inhibitor use was associated with a small increase in erythropoietin (EPO) compared with control in pooled randomized trials.Difference in change: 2.11 mIU/mL (95% CI, 0.50 to 3.71; P = .01).

“Secondary outcomes were changes in red blood cell concentration, erythropoietin (EPO), and iron measures (serum iron, ferritin, transferrin saturation, and hepcidin).”
Claim 3 of 5SupportedResearch led by internist-nephrologist Dr. Michele Eisenga shows that SGLT2 inhibitors consistently increase hemoglobin and hematocrit levels.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the central finding that SGLT2 inhibitors were associated with statistically significant increases in hemoglobin and hematocrit in a large randomized-trial meta-analysis. The profile does not independently verify the named lead researcher, but the scientific claim about hemoglobin and hematocrit is supported.

1

Study evidence

SGLT2 inhibitor use was associated with a greater increase in hemoglobin from baseline to follow-up compared with control.Difference in change: +0.60 g/dL (95% CI, 0.55 to 0.66 g/dL); P < .001

“A Systematic Review and Meta-Analysis of Randomized Clinical Trials.”
Claim 4 of 5SupportedBy combining data from 85 randomized clinical trials involving more than 70,000 participants, the researchers found that these drugs may influence the way the body regulates iron and produces red blood cells.View evidenceHide evidence

Why this verdict

The profile reports 85 randomized, double-masked trials with 70,543 participants and secondary outcomes involving erythropoiesis and iron-metabolism markers. The hedged wording that the drugs 'may influence' iron regulation and red-blood-cell production is consistent with the abstract-level biomarker findings.

1

Study evidence

SGLT2 inhibitor use was associated with a greater increase in hemoglobin from baseline to follow-up compared with control.Difference in change: +0.60 g/dL (95% CI, 0.55 to 0.66 g/dL); P < .001

“A Systematic Review and Meta-Analysis of Randomized Clinical Trials.”
2

Study evidence

SGLT2 inhibitor use was associated with a small increase in erythropoietin (EPO) compared with control in pooled randomized trials.Difference in change: 2.11 mIU/mL (95% CI, 0.50 to 3.71; P = .01).

“Secondary outcomes were changes in red blood cell concentration, erythropoietin (EPO), and iron measures (serum iron, ferritin, transferrin saturation, and hepcidin).”
Claim 5 of 5SupportedCompared with placebo or other glucose-lowering medications, SGLT2 inhibitors were associated with higher hemoglobin and hematocrit after a median follow-up of 24 weeks; on average, hemoglobin increased by 0.60 g/dL and hematocrit by 2.36%.View evidenceHide evidence

As statedhemoglobin +0.60 g/dL; hematocrit +2.36%

Why this verdict

The profile reports a median trial duration of 24 weeks and pooled differences of +0.60 g/dL for hemoglobin and +2.36 percentage points for hematocrit versus placebo or active comparators. The story’s hematocrit wording as '+2.36%' is slightly imprecise because the paper profile states percentage points, but the result is otherwise supported.

1

Study evidence

SGLT2 inhibitor use was associated with a greater increase in hemoglobin from baseline to follow-up compared with control.Difference in change: +0.60 g/dL (95% CI, 0.55 to 0.66 g/dL); P < .001

“A Systematic Review and Meta-Analysis of Randomized Clinical Trials.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • At abstract depth, the profile verifies increased EPO and decreased transferrin saturation but does not enumerate all secondary biomarker results.

    The story presents ferritin decrease and unchanged serum iron as definite findings, but those specific results are not verifiable from the abstract-level profile.

    From Systematic review and random-effects meta-analysis (secondary biomarker outcomes)

  • Median follow-up was 24 weeks, so longer-term hematologic and biomarker effects are less represented.

    The story reports the median follow-up of 24 weeks but does not frame this as a limitation on longer-term interpretation.

    From Systematic review and random-effects meta-analysis of randomized, double-masked clinical trials; Systematic review and r

  • Most trials compared SGLT2 inhibitors with placebo, with fewer active-comparator trials.

    The story says comparisons were with placebo or other glucose-lowering medications, but it does not note the imbalance toward placebo-controlled evidence.

    From Systematic review and random-effects meta-analysis of randomized, double-masked clinical trials

  • The abstract does not provide detailed heterogeneity or risk-of-bias results.

    The story does not mention the absence of detailed heterogeneity or risk-of-bias information at abstract depth.

    From Systematic review and random-effects meta-analysis of randomized, double-masked clinical trials; Systematic review and r

6 things the story did carry across
  • The paper is a systematic review and random-effects meta-analysis of randomized, double-masked clinical trials comparing SGLT2 inhibitors with placebo or active comparators.
  • The analysis included 85 trials and 70,543 participants.
  • Primary outcomes were changes in hemoglobin and hematocrit from baseline to follow-up.
  • SGLT2 inhibitors were associated with small but statistically significant increases in hemoglobin and hematocrit.
  • Secondary outcomes included erythropoiesis and iron-metabolism markers such as EPO, serum iron, ferritin, transferrin saturation, hepcidin, and RBC concentration.
  • The clinical significance of the hemoglobin, hematocrit, and biomarker changes remains unclear.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataQuantify the association of SGLT2 inhibitor use (vs placebo or active comparator) with changes in hemoglobin and hematocrit in randomized clinical trials.Systematic review and random-effects meta-analysis of randomized, double-masked clinical trialsExpand

In plain English

Systematic review and random-effects meta-analysis of 85 randomized, double-masked trials (70,543 participants) evaluating SGLT2 inhibitor use versus placebo or active comparators; SGLT2 inhibitors were associated with small, statistically significant increases in hemoglobin and hematocrit from baseline to follow-up compared with control, though the clinical significance is unclear.

Key findings

  • SGLT2 inhibitor use was associated with a greater increase in hemoglobin from baseline to follow-up compared with control.Difference in change: +0.60 g/dL (95% CI, 0.55 to 0.66 g/dL); P < .001
  • SGLT2 inhibitor use was associated with a greater increase in hematocrit from baseline to follow-up compared with control.Difference in change: +2.36 percentage points (95% CI, 2.19% to 2.52%); P < .001
“A Systematic Review and Meta-Analysis of Randomized Clinical Trials.”
What this piece can’t prove
  • Median follow-up was 24 weeks, so longer-term hematologic effects are less represented.
  • Majority of comparisons were versus placebo; fewer active-comparator trials were available.

1 further detail could not be confirmed from the summary.

2secondary dataAssess associations of SGLT2 inhibitor use with markers of erythropoiesis and iron metabolism (eg, RBC concentration, EPO, serum iron, ferritin, transferrin saturation, hepcidin) in randomized clinical trials.Systematic review and random-effects meta-analysis (secondary biomarker outcomes)Expand

In plain English

Systematic review and random-effects meta-analysis of 85 randomized, double-masked clinical trials (70,543 participants) evaluating associations between SGLT2 inhibitor use and secondary biomarkers of erythropoiesis and iron metabolism (red blood cell concentration, erythropoietin, serum iron, ferritin, transferrin saturation, hepcidin). In the pooled analyses reported in the abstract, SGLT2 inhibitor use was associated with a small increase in erythropoietin and a small decrease in transferrin saturation; the abstract reports that 4 of 6 prespecified secondary outcomes showed statistically significant associations but does not list all effect estimates in the abstract text.

Key findings

  • SGLT2 inhibitor use was associated with a small increase in erythropoietin (EPO) compared with control in pooled randomized trials.Difference in change: 2.11 mIU/mL (95% CI, 0.50 to 3.71; P = .01).
  • SGLT2 inhibitor use was associated with a small decrease in transferrin saturation compared with control in pooled randomized trials.Difference in change: −0.84% (95% CI, −1.21 to −0.47; P < .001).
“Secondary outcomes were changes in red blood cell concentration, erythropoietin (EPO), and iron measures (serum iron, ferritin, transferrin saturation, and hepcidin).”
What this piece can’t prove
  • The abstract does not enumerate which of the remaining secondary outcomes (beyond EPO and transferrin saturation) were statistically significant nor provide their effect sizes.
  • Median trial duration was 24 weeks (IQR 12–32), so longer-term biomarker effects are not characterized by the summary provided.
  • The abstract states that the clinical significance of the observed biomarker changes is unclear.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

And 32 more candidates considered.